文献速递前列腺癌

磁共振引导经尿道超声消融治疗局限性前列腺癌:前瞻性I期研究3年结果

Magnetic resonance imaging-guided transurethral ultrasound ablation in patients with localised prostate cancer: 3-year outcomes of a prospective Phase I study.
PubMed 文献 · BJU Int · 2020-11-01

该前瞻性I期研究纳入30例局限性前列腺癌男性,行MRI引导经尿道超声消融(TULSA)近全腺消融,保留10%外周前列腺组织。3年随访22例,未出现新的严重不良事件,泌尿与肠道功能稳定,勃起功能1年恢复后3年稳定;PSA中位最低值0.33 ng/mL,3年时0.8 ng/mL;系列活检显示34%有临床显著疾病,59%有任何癌症;7例接受挽救治疗无并发症。

要点

  • TULSA近全腺消融在3年随访中安全,无新增严重不良事件,功能稳定。
  • PSA中位最低值0.33 ng/mL,3年时0.8 ng/mL,活检可预测疾病控制。
  • 3年时7例接受挽救治疗(含6例前列腺切除术),无并发症。

核心结论

  • TULSA对局限性前列腺癌男性提供安全精确的消融,PSA和活检结果可预测,不影响功能且不阻碍挽救治疗。

研究设计与样本

  • 前瞻性I期研究,30例局限性前列腺癌男性接受MRI引导TULSA近全腺消融,保留10%外周前列腺组织。
  • 12个月活检和MRI后每半年随访PSA、不良事件和生活质量,3年重复系统活检。

主要发现

  • 3年随访完成22例,1至3年间无新的严重或重度不良事件,泌尿和肠道功能稳定,勃起功能1年恢复后3年稳定。
  • PSA下降95%至中位最低值0.33(0.1-0.4)ng/mL,3年时稳定在0.8(0.4-1.6)ng/mL。
  • 系列活检发现10/29(34%)有临床显著疾病,17/29(59%)有任何癌症;3年内7例复发(4例组织学,3例生化)并接受挽救治疗无并发症(含6例前列腺切除术)。
  • 3年时22例中3例拒绝活检,2例(9%)有临床显著疾病(1例新发,1例持续)。
  • 挽救治疗需求的预测因素包括消融覆盖范围较小和PSA最低值较高。

临床怎么用

  • TULSA可作为局限性前列腺癌的消融选项,需告知患者3年活检仍可能发现临床显著疾病。
  • 术后应监测PSA最低值和消融覆盖范围,以评估挽救治疗风险。
  • TULSA不影响后续挽救治疗(如前列腺切除术)的可行性。

局限性

  • I期研究样本量小(30例),3年随访仅22例完成。
  • 3年时3例拒绝活检,可能低估疾病检出。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To report the 3-year follow-up of a Phase I study of magnetic resonance imaging (MRI)-guided transurethral ultrasound ablation (TULSA) in 30 men with localised prostate cancer. Favourable 12-month safety and ablation precision were previously described. PATIENTS AND METHODS: As a mandated safety criterion, TULSA was delivered as near whole-gland ablation, applying 3-mm margins sparing 10% of peripheral prostate tissue in 30 men. After 12-month biopsy and MRI, biannual follow-up included prostate-specific antigen (PSA), adverse events (AEs), and functional quality-of-life assessment, with repeat systematic biopsy at 3 years. RESULTS: A 3-year follow-up was completed by 22 patients. Between 1 and 3 years, there were no new serious or severe AEs. Urinary and bowel function remained stable. Erectile function recovered by 1 year and was stable at 3 years. The PSA level decreased 95% to a median (interquartile range) nadir of 0.33 (0.1-0.4) ng/mL, stable to 0.8 (0.4-1.6) ng/mL at 3 years. Serial biopsies identified clinically significant disease in 10/29 men (34%) and any cancer in 17/29 (59%). By 3 years, seven men had recurrence (four histological, three biochemical) and had undergone salvage therapy without complications (including six prostatectomies). At 3 years, three of 22 men refused biopsy, and two of the 22 (9%) had clinically significant disease (one new, one persistent). Predictors of salvage therapy requirement included less extensive ablation coverage and higher PSA nadir. CONCLUSION: With 3-year Phase I follow-up, TULSA demonstrates safe and precise ablation for men with localised prostate cancer, providing predictable PSA and biopsy outcomes, without affecting functional abilities or precluding salvage therapy.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Nair SM, Hatiboglu G, Relle J, et al. Magnetic resonance imaging-guided transurethral ultrasound ablation in patients with localised prostate cancer: 3-year outcomes of a prospective Phase I study. BJU Int. 2020. PMID: 33037765. doi:10.1111/bju.15268

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。